Antibodies That Target Human Protein Tyrosine Phosphatase-Beta (HPTP-BETA) and Methods of Use Thereof to Treat Ocular Conditions
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 62/364,381, filed Jul 20, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,253,094 | Antibodies That Target Human Protein Tyrosine Phosphatase-Beta (HPTP-BETA) and Methods of Use Thereof to Treat Ocular Conditions In force · High confidence | Eyepoint, Inc. | In force | High confidence | ||
| US 10,597,452 | Methods of Treating Ocular Conditions by Administering Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-BETA) In force · High confidence | Eyepoint, Inc. | In force | High confidence | ||
| US 10,604,569 | Humanized Monoclonal Antibodies That Target Protein Tyrosine Phosphatase-Beta (Hptp-Beta / Ve-Ptp) In force · High confidence | Eyepoint, Inc. | In force | High confidence | ||
| US 11,136,389 | Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-BETA) In force · High confidence | Eyepoint, Inc. | In force | High confidence | ||
| US 11,180,551 | Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-Beta) In force · High confidence | Eyepoint, Inc. | In force | High confidence | ||
| US 12,145,986 | A Method of Treating an Ocular Condition by Administering a Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-Beta) In force · Medium confidence | Eyepoint, Inc. | In force | Medium confidence |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.